Suchergebnisse
![[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens](https://www.sharewise.com/assets/news/news4-705b1ede251f597c3fb0a237db1c4cf950e74deda55e184efa81c1990bbe8926.png)
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens
- Konzernverkäufe stiegen in den ersten drei Monaten um 6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -5% und auf USD-Basis2 9%) aufgrund hoher Nachfrage nach innovativen Medikamenten
SoundHound vs. Cerence: Which Voice AI Stock Has Stronger Potential?
Voice artificial intelligence is becoming one of the most important software themes in 2026 as automakers, restaurants, enterprises and digital platforms look to improve customer engagement
Is International Seaways (INSW) Outperforming Other Transportation Stocks This Year?
Investors interested in Transportation stocks should always be looking to find the best-performing companies in the group. International Seaways (INSW) is a stock that can certainly grab the
RHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
Swiss pharma giant Roche Holding AG's RHHBY first-quarter 2026 results were affected by currency headwinds.
Sales totaled $18.8 billion, which beat the Zacks Consensus Estimate of $18.43 billion.
Are Basic Materials Stocks Lagging Denison Mine Corp (DNN) This Year?
For those looking to find strong Basic Materials stocks, it is prudent to search for companies in the group that are outperforming their peers. Denison Mine (DNN) is a stock that can certainly grab
Are Utilities Stocks Lagging Consolidated Edison (ED) This Year?
Investors interested in Utilities stocks should always be looking to find the best-performing companies in the group. Consolidated Edison (ED) is a stock that can certainly grab the attention of
Will Lower Gardasil Sales Hurt MRK's Vaccines Sales in Q1 Earnings?
Merck MRK continues to encounter persistent challenges with its second-largest product, Gardasil, a vaccine approved to prevent certain cancers caused by the human papillomavirus. While Gardasil’s